Epigenomics of High Risk Pediatric T Cell Leukemia |
New York University School of Medicine / Iannis Aifantis, PhD |
Reach Grants |
2013 |
New York |
Development of a Pharmacodynamic Marker of EWS-FLI1 Activity to Aid in the Clinical Translation of Targeted Therapies for Ewing sarcoma |
Van Andel Research Institute / Patrick Grohar, MD, PhD |
Reach Grants |
2013 |
Michigan |
Astatine-211 Meta-Astatobenzylguanidine ([211At]MABG) Targeted Radiotherapy for Disseminated Neuroblastoma |
Children’s Hospital of Philadelphia / John Maris, MD |
Reach Grants |
2016 |
Pennsylvania |
Targeting PLK1 as a Common Mechanism in Ph-like ALL |
University of Texas M.D. Anderson Cancer Center / Joya Chandra, PhD |
Reach Grants |
2016 |
Texas |
Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy |
New York Medical College / Mitchell Cairo, MD |
Reach Grants |
2023 |
New York |
Therapeutic Targeting of PGBD5-induced DNA Repair Dependency in Pediatric Solid Tumors |
Memorial Sloan-Kettering Cancer Center / Alex Kentsis, MD/PhD |
Reach Grants |
2017 |
New York |
Feasibility Study of Dual Inhibition of MDM2 and Tubulin in Treatment of AML |
Emory University / Muxiang Zhou, MD |
Reach Grants |
2023 |
Georgia |
Dual PTK7/GD2 Gamma Delta CAR T Cell Therapy for Neuroblastoma |
Emory University / Kelly Goldsmith, MD & H. Trent Spencer, PhD & Chris B. Doering, PhD |
Reach Grants |
2021 |
Georgia |
Novel Therapy for Pediatric Leukemia Patients with NUP98 Translocations |
The Regents of the University of Michigan / Jolanta Grembecka, PhD |
Reach Grants |
2022 |
Michigan |
Immuno-therapeutic Targeting of CD56 in CBA2T3/GLIS2-AML in Children |
Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD/PhD |
Reach Grants |
2018 |
Washington |